Clinical vitamin A deficiency (as defined by night blindness) · general population over 2 years of age
It is very uncertain whether staple foods fortified with vitamin A changes clinical vitamin A deficiency (defined as night blindness) compared with same unfortified staple foods (very low certainty).
1 finding from 1 review
Any adverse effects (e.g. hypervitaminosis A, as defined by the trialists) · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in recurrent venous thromboembolism compared with standard therapy (moderate certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether fondaparinux plus vitamin K antagonist changes all harmful effects compared with standard therapy (very low certainty).
1 finding from 1 review
Neuropathy due to vitamin E deficiency · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Retinopathy due to vitamin E deficiency · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vitamin E total lipid ratio · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vitamin E levels in serum: umol/L · adults and children with cystic fibrosis
1 finding from 1 review
no estimate extracted
6 participants
GRADE not reported
Persons with hypercalcaemia ‐ Vitamin D (D2, D3 or 25(OH)D) plus calcium (1 year estimate) · post‐menopausal women and older people at risk of osteoporotic fractures
Vitamin D [D2, D3 or 25(OH)D] plus calcium showed no clear difference in persons with hypercalcaemia ‐ Vitamin D (D2, D3 or 25(OH)D) plus… compared with control or placebo (low certainty).
1 finding from 1 review